Navigation Links
SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
Date:4/16/2008

DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that that it has identified a lead PIM kinase inhibitor, SGI-1776, that causes tumor regression in acute myologenous leukemia (AML) xenograft models (Abstract No. 4083).

In an oral presentation entitled, "A potent small molecule PIM kinase inhibitor with activity in cell lines from hematological and solid malignancies," Dr. Steven Warner detailed how scientists used SuperGen's CLIMB(TM) technology to build a model that allowed for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as a potent and selective inhibitor of the PIM kinases, inducing apoptosis and cell cycle arrest, thereby causing a reduction in phospho-BAD levels and enhancement of mTOR inhibition in vitro. Most notably, SGI-1776 induced significant tumor regression in MV-4-11 (prostate cancer) and MOLM-13 (AML) xenograft models.

"We are encouraged by these promising data. Our PIM kinase inhibitor, SGI-1776, may prove to be a treatment for AML, and other malignancies that over express PIM kinase," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "The data also provide support for the use of our CLIMB(TM) technology to identify and rapidly advance candidates into the clinic. We plan to initiate Phase 1 clinical trials with SGI-1776 in solid tumors and leukemias later this year. SGI-1776 may become the first drug in this class of inhibitors to enter the clinic."

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns

SuperGen, Inc.

SVP, Corporate Communications & Business Development

Tel: (925) 560-0100

E-mail: tenns@supergen.com

Mary M. Vegh

SuperGen, Inc.

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Show SuperGens MP-470 is Safe in Humans
2. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
3. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
5. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
6. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
9. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
(Date:4/27/2016)... , April 27, 2016 ... over USD 2.14 billion by 2022, according to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... advancement affecting the efficiency and accuracy delivered by ... persistent demand for novel urinalysis instruments and consumables. ...
(Date:4/26/2016)... CHICAGO , April 26, 2016 Hill-Rom Holdings, ... to a management presentation at the Deutsche Bank 41 st ... at 2:50 p.m. EDT. You are invited to ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas ... one hour after conclusion of the live event and accessible ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online ... cosmetictown.com . The forum section was recently revamped and upgraded to allow even more ... in use across the country. , According to the senior editor of Cosmetic Town, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... has been collaborating with doctors and hospitals to make transformative changes in how ... leading cell therapy minds this week in discussing breakthroughs in cellular medicine to ...
(Date:4/28/2016)... Washington D.C. (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us ... and Prevention (CDC), a stroke is the fourth leading cause of death in the United ... country, with almost a quarter of them in individuals under 65 years old. A ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... M.D. has been named a Top Doc in Physical Medicine and Rehabilitation by ... with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership across ...
(Date:4/28/2016)... ... 2016 , ... Denise McCormick Baich had written poetry dating back to her childhood, but after ... a tsunami and took on a more spiritual tone. The desire to put the words ... with it than just file it away. Friends would ask her how she wrote such ...
Breaking Medicine News(10 mins):